JP2024099041A5 - - Google Patents

Download PDF

Info

Publication number
JP2024099041A5
JP2024099041A5 JP2024073463A JP2024073463A JP2024099041A5 JP 2024099041 A5 JP2024099041 A5 JP 2024099041A5 JP 2024073463 A JP2024073463 A JP 2024073463A JP 2024073463 A JP2024073463 A JP 2024073463A JP 2024099041 A5 JP2024099041 A5 JP 2024099041A5
Authority
JP
Japan
Prior art keywords
group
atom
acceptable salt
compound according
pharmacologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2024073463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024099041A (ja
Filing date
Publication date
Priority claimed from PCT/JP2019/035198 external-priority patent/WO2020050406A1/ja
Application filed filed Critical
Publication of JP2024099041A publication Critical patent/JP2024099041A/ja
Publication of JP2024099041A5 publication Critical patent/JP2024099041A5/ja
Priority to JP2025203466A priority Critical patent/JP2026026166A/ja
Ceased legal-status Critical Current

Links

JP2024073463A 2018-09-06 2024-04-30 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート Ceased JP2024099041A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025203466A JP2026026166A (ja) 2018-09-06 2025-11-26 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2018167369 2018-09-06
JP2018167369 2018-09-06
PCT/JP2019/035198 WO2020050406A1 (ja) 2018-09-06 2019-09-06 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート
JP2020541321A JP7254818B2 (ja) 2018-09-06 2019-09-06 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート
JP2023050936A JP7483975B2 (ja) 2018-09-06 2023-03-28 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023050936A Division JP7483975B2 (ja) 2018-09-06 2023-03-28 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025203466A Division JP2026026166A (ja) 2018-09-06 2025-11-26 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート

Publications (2)

Publication Number Publication Date
JP2024099041A JP2024099041A (ja) 2024-07-24
JP2024099041A5 true JP2024099041A5 (cg-RX-API-DMAC7.html) 2025-01-14

Family

ID=69722459

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020541321A Active JP7254818B2 (ja) 2018-09-06 2019-09-06 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート
JP2023050936A Active JP7483975B2 (ja) 2018-09-06 2023-03-28 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート
JP2024073463A Ceased JP2024099041A (ja) 2018-09-06 2024-04-30 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート
JP2025203466A Pending JP2026026166A (ja) 2018-09-06 2025-11-26 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020541321A Active JP7254818B2 (ja) 2018-09-06 2019-09-06 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート
JP2023050936A Active JP7483975B2 (ja) 2018-09-06 2023-03-28 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025203466A Pending JP2026026166A (ja) 2018-09-06 2025-11-26 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート

Country Status (26)

Country Link
US (2) US12370263B2 (cg-RX-API-DMAC7.html)
EP (2) EP3848054B1 (cg-RX-API-DMAC7.html)
JP (4) JP7254818B2 (cg-RX-API-DMAC7.html)
KR (4) KR102567591B1 (cg-RX-API-DMAC7.html)
CN (3) CN118846110A (cg-RX-API-DMAC7.html)
AU (2) AU2019337051B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021003472A2 (cg-RX-API-DMAC7.html)
CA (2) CA3251690A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021004032A2 (cg-RX-API-DMAC7.html)
DK (1) DK3848054T3 (cg-RX-API-DMAC7.html)
ES (1) ES3017008T3 (cg-RX-API-DMAC7.html)
FI (1) FI3848054T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250345T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071437T2 (cg-RX-API-DMAC7.html)
IL (2) IL281247B2 (cg-RX-API-DMAC7.html)
LT (1) LT3848054T (cg-RX-API-DMAC7.html)
MX (1) MX2021002107A (cg-RX-API-DMAC7.html)
PH (1) PH12021550442A1 (cg-RX-API-DMAC7.html)
PL (1) PL3848054T3 (cg-RX-API-DMAC7.html)
PT (1) PT3848054T (cg-RX-API-DMAC7.html)
RS (1) RS66662B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101526YA (cg-RX-API-DMAC7.html)
SI (1) SI3848054T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500141T1 (cg-RX-API-DMAC7.html)
TW (3) TWI905974B (cg-RX-API-DMAC7.html)
WO (1) WO2020050406A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118846110A (zh) 2018-09-06 2024-10-29 第一三共株式会社 抗体药物偶联物
US12678512B2 (en) * 2020-03-06 2026-07-14 Daiichi Sankyo Company, Limited Anti-EGFR antibody-drug conjugate with a cyclic dinucleotide derivative
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
EP4209506A4 (en) * 2020-09-02 2024-10-09 Daiichi Sankyo Company, Limited NEW ENDO-N-ACETYL GLUCOSAMINIDASE
CN116867795A (zh) * 2021-02-01 2023-10-10 第一三共株式会社 抗体-免疫刺激剂偶联物的新型制造方法
TW202241454A (zh) 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體-免疫賦活化劑共軛物之新穎製造方法
JP7721635B2 (ja) 2021-03-12 2025-08-12 第一三共株式会社 糖鎖及び糖鎖を含む医薬品の製造方法
WO2022226420A2 (en) * 2021-04-23 2022-10-27 University Of Maryland, College Park An fc glycan remodeling platform method for site-specific antibody conjugation and applications thereof
US20250057967A2 (en) * 2021-06-25 2025-02-20 Bolt Biotherapeutics, Inc. Bis-benzimidazole sting agonist immunoconjugates, and uses thereof
CA3224492A1 (en) 2021-07-19 2023-01-26 Xiaojun Han Immunoconjugates and methods
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CN115703845A (zh) * 2021-08-05 2023-02-17 中国科学院上海药物研究所 寡糖连接子与侧链亲水性片段组合的糖链定点抗体-药物偶联物,其制法及用途
WO2023061405A1 (zh) * 2021-10-12 2023-04-20 成都科岭源医药技术有限公司 一种高稳定性的靶向接头-药物偶联物
CA3236388A1 (en) 2021-10-29 2023-05-04 Daiichi Sankyo Company, Limited Novel oligosaccharide, manufacturing intermediate for novel oligosaccharide, and method for manufacturing these
WO2023100829A1 (ja) 2021-11-30 2023-06-08 第一三共株式会社 プロテアーゼ分解性マスク抗体
AU2023218678A1 (en) 2022-02-09 2024-08-01 Daiichi Sankyo Company, Limited Environmentally responsive masked antibody and use thereof
IL315341A (en) 2022-03-02 2024-10-01 Daiichi Sankyo Co Ltd METHOD FOR PRODUCING Fc-CONTAINING MOLECULE
JP2025166269A (ja) * 2022-07-29 2025-11-06 第一三共株式会社 抗腫瘍効果を有する抗体薬物複合体の新規製造方法
KR20250054799A (ko) 2022-08-29 2025-04-23 다이이찌 산쿄 가부시키가이샤 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트
KR20250064682A (ko) 2022-09-09 2025-05-09 다이이찌 산쿄 가부시키가이샤 신규 올리고당, 그 올리고당의 제조 중간체, 및 그것들의 제조 방법
WO2024107827A1 (en) * 2022-11-16 2024-05-23 The Broad Institute, Inc. Therapeutic exploitation of sting channel activity
EP4626553A2 (en) 2022-11-30 2025-10-08 Regeneron Pharmaceuticals, Inc. Tlr7 agonists and antibody-drug-conjugates thereof
EP4737483A1 (en) 2023-06-30 2026-05-06 Daiichi Sankyo Company, Limited Antibody-drug conjugate production method including purification step using activated carbon material
TW202545568A (zh) 2024-01-29 2025-12-01 日商第一三共股份有限公司 抗her2抗體-藥物結合物與其他劑之組合
TW202543682A (zh) * 2024-02-28 2025-11-16 日商第一三共股份有限公司 抗cdh6抗體—藥物結合物與其他劑之組合

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
EP1506285B1 (en) 2001-11-01 2010-12-08 Uab Research Foundation Combinations of anti-dr5 antibodies and anti-dr4 antibodies and other therapeutic agents
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
CA2647632C (en) 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
WO2009028639A1 (ja) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗epha2抗体
JP5566226B2 (ja) 2009-09-03 2014-08-06 旭化成株式会社 11糖シアリルオリゴ糖ペプチドの製造方法
US9175326B2 (en) 2011-03-03 2015-11-03 University Of Maryland, Baltimore Transglycosylation activity of glycosynthase mutants of an endo-beta-N-acetylglucosaminidase (endo-D) from streptococcus pneumoniae
US10851174B2 (en) 2011-03-03 2020-12-01 University Of Maryland, Baltimore Core fucosylated glycopeptides and glycoproteins: chemoenzymatic synthesis and uses thereof
JP6282232B2 (ja) 2012-02-10 2018-02-21 ユニバーシティー オブ メリーランド,ボルティモア 抗体及びそのFcフラグメントの酵素化学的糖鎖改変
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
SG11201502796RA (en) 2012-12-13 2015-05-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
JP2016506408A (ja) 2012-12-19 2016-03-03 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
WO2015057065A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
WO2015057064A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
WO2015057066A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
JP2016538877A (ja) 2013-10-14 2016-12-15 シンアフィックス ビー.ブイ. 修飾糖タンパク質、タンパク質コンジュゲート及びそれらの調製方法
EP3071229A4 (en) 2013-11-22 2017-05-10 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
EP3152217B1 (en) 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
DE102014214408A1 (de) 2014-07-23 2016-01-28 Wacker Chemie Ag Härtbare Organopolysiloxanzusammensetzungen
PL3608403T3 (pl) 2014-12-15 2025-06-23 Henkel Ag & Co. Kgaa Kompozycja detergentowa zawierająca warianty subtylazy
US11559581B2 (en) 2015-01-09 2023-01-24 Oxford University Innovation Limited Antibody conjugates and methods of making the antibody conjugates
TWI706958B (zh) 2015-03-10 2020-10-11 美商艾杜諾生物科技公司 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
WO2016161372A1 (en) 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
CA2990572C (en) * 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
TWI730972B (zh) 2015-07-16 2021-06-21 日商第一三共股份有限公司 新穎EndoS變異酵素及使用其之經糖鏈重塑之含Fc區域的分子之製造方法
US10246468B2 (en) 2015-08-12 2019-04-02 Hoffmann-La Roche Inc. BACE1 inhibitors
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
KR20180066241A (ko) 2015-10-28 2018-06-18 아두로 바이오테크, 인코포레이티드 “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법
CR20180229A (es) * 2015-10-29 2018-08-24 Novartis Ag Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
JP6411676B2 (ja) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingの調節因子としての環状プリンジヌクレオチド
DE212016000029U1 (de) 2015-12-07 2017-07-30 Opi Vi - Ip Holdco Llc Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
US20170158772A1 (en) 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
SMT202500412T1 (it) 2016-01-11 2025-11-10 Innate Tumor Immunity Inc Dinucleotidi ciclici per il trattamento di condizioni associate all’attività di sting quali il cancro
WO2017123657A1 (en) 2016-01-11 2017-07-20 Gary Glick Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
IL280430B2 (en) 2016-03-18 2023-11-01 Univ Texas Cyclic dinucleotide compounds and methods of use
SG10201900628RA (en) 2016-04-07 2019-02-27 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
AU2017246802B2 (en) 2016-04-07 2021-04-01 Chevron U.S.A. Inc. Smart gel sealants for well systems
US11486223B2 (en) 2016-04-07 2022-11-01 Chevron U.S.A. Inc. Method for sealing a void in a well using smart gels
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
CN109462989A (zh) 2016-07-01 2019-03-12 第三共株式会社 Hanp-含fc分子缀合物
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
CA3029644A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
US20190345191A1 (en) 2016-08-31 2019-11-14 Innate Tumor Immunity, Inc. Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
JP6636673B2 (ja) 2016-10-04 2020-01-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. STINGアゴニストとしてのベンゾ[b]チオフェン化合物
WO2018066626A1 (ja) 2016-10-07 2018-04-12 第一三共株式会社 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療
WO2018065360A1 (de) 2016-10-07 2018-04-12 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
JP2018090562A (ja) 2016-12-01 2018-06-14 武田薬品工業株式会社 環状ジヌクレオチド
WO2018100558A2 (en) 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
RU2019122598A (ru) 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. Циклические динуклеотидные агонисты sting для лечения рака
CA3049791A1 (en) * 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
TWI926682B (zh) 2017-05-15 2026-05-21 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
JP6967739B2 (ja) 2017-11-14 2021-11-17 パナソニックIpマネジメント株式会社 給湯機
CN118846110A (zh) 2018-09-06 2024-10-29 第一三共株式会社 抗体药物偶联物

Similar Documents

Publication Publication Date Title
JP2023105175A (ja) グルクロニド薬物-リンカーの調製のためのプロセスおよびその中間体
US7968586B2 (en) Cytotoxic compounds and conjugates
WO2017165851A1 (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
JP2021523225A5 (cg-RX-API-DMAC7.html)
US20060247295A1 (en) Cytotoxic compounds and conjugates with cleavable substrates
WO2018148650A1 (en) Trigger-activatable sugar conjugates for cancer-selective labeling and targeting
JP2022553702A5 (cg-RX-API-DMAC7.html)
HRP20250345T1 (hr) Konjugati antitijelo - lijek derivata cikličnih dinukleotida
KR20080068084A (ko) 씨씨-1065 유사체를 제조하기 위한 방법 및 화합물
CN103570792B (zh) 蟾毒灵衍生物、其制备方法、药物组合物及用途
JP2006511534A5 (cg-RX-API-DMAC7.html)
TR201802539T4 (tr) CC-1065 analoglarının ve bifonksiyonel bağlayıcıların konjugatları.
JP2024532845A5 (cg-RX-API-DMAC7.html)
PL195014B1 (pl) Nowe, podstawione pochodne kwasu N-benzyloindol-3-iloglioksylowego o działaniu przeciwnowotworowym oraz ich zastosowanie
CN111417408B (zh) 药物接头化合物的制备方法
JP2026507549A (ja) 改良された特性を有するテトラジン類
JP5612467B2 (ja) Fmocをベースとした加水分解性リンカーの調製方法
KR20180055135A (ko) 벤조사이아졸 유도체가 결합된 리간드-금속 복합체 및 이의 제조 방법
JP2022545181A5 (cg-RX-API-DMAC7.html)
KR20170041562A (ko) 벤조셀레노펜계 화합물 및 이를 포함하는 항체-약물 결합체
JP2002533418A (ja) アントラキノン抗癌剤
US20250161506A1 (en) Antibody Drug Conjugate Based on Metal N-Heterocyclic Carbene Complex, a Method of Preparing the Same and the Use of the Same in Anticancer Treatment
JP4590198B2 (ja) 葉酸誘導体の製造方法
CN116715678B (zh) 一种吲哚糖碳苷类大环化合物及其制备方法与应用
FI3441386T3 (fi) Menetelmä yksöissuojattujen bifunktionaalisten aihiolääkkeiden syntetisoimiseksi ja niihin perustuvia vasta-aine-lääkekonjugaatteja sekä menetelmä vasta-aine-lääkekonjugaattien valmistamiseksi